HomeInsightsResults

Zydus Lifesciences Ltd Quarterly Result

Zydus Lifesciences Ltd Quarterly Result

stocks purchased

₹ 1.1 Cr

Volume Transacted

(Nov 21, 2024)

stocks purchased

11.2 K

Stocks Traded

(Nov 21, 2024)

Last Updated on: Nov 22, 2024

Image

Zydus Lifesciences Ltd

NSE: ZYDUSLIFE

Net Profit

₹ 898.1

Last updated on: Nov 22, 2024

Key Highlights

  • The revenue of Zydus Lifesciences Ltd for the Sep '24 is ₹ 5305 crore as compare to the Jun '24 revenue of ₹ 6270 crore. This represent the decline of -15.392223%.
  • The ebitda of Zydus Lifesciences Ltd for the Sep '24 is ₹ 1529 crore as compare to the Jun '24 ebitda of ₹ 2147 crore. This represent the decline of -28.749065%.
  • The net profit of Zydus Lifesciences Ltd for the Sep '24 is ₹ 898.1 crore as compare to the Jun '24 net profit of ₹ 1463 crore. This represent the decline of -38.637608%.

Results Analysis

Market Price of Zydus Lifesciences Ltd

1M

1Y

3Y

5Y

Monitoring Zydus Lifesciences Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
21 Nov 2024944.25
19 Nov 2024946.9
18 Nov 2024944.95
14 Nov 2024958.05
13 Nov 2024963.6
12 Nov 2024950.1
11 Nov 2024968.55
08 Nov 2024968.65
07 Nov 2024972.6
06 Nov 2024995

Historical Revenue of Zydus Lifesciences Ltd

No data available

* All values are in crore

Historical EBITDA of Zydus Lifesciences Ltd

No data available

* All values are in crore

Historical Net Profit of Zydus Lifesciences Ltd

No data available

* All values are in crore

Zydus Lifesciences Ltd News Hub

News

Zydus Life Q2 PAT rises 14% YoY to Rs 911 cr

Revenue from operations grew 19.87% year on year (YoY) to Rs 5,237 crore in the quarter en...

Read more

12 Nov 202415:22

News

Zydus Lifesciences to table results

Zydus Lifesciences will hold a meeting of the Board of Directors of the Company on 12 Nove...

Read more

31 Oct 202411:58

News

Zydus Life rises on in-principle approval from WHO for typhoid vaccine

ZyVac TCV is now eligible for purchase by United Nations (UN) agencies. It is indigenously...

Read more

23 Oct 202414:50

News

Zydus receives USFDA approval for Fludrocortisone Acetate Tablets

Zydus Lifesciences has received final approval from the United States Food and Drug Admini...

Read more

18 Oct 202409:29

News

Zydus Life gets final approval from USFDA for Fludrocortisone Acetate tab

Fludrocortisone Acetate tablets are indicated as partial replacement therapy for primary a...

Read more

18 Oct 202412:47

News

Zydus partners with ICMR to initiate Phase 2 clinical trials of Desidustat oral tablet for treating sickle cell disease

Zydus Lifesciences has formalized the Memorandum of Agreement (MoA) with Indian Council of...

Read more

15 Oct 202410:08

Document

Annual Reports

Annual Report 2024

dropdown
download

Credit Ratings

Credit Report 2024

dropdown
download

Concalls

Sep 2021

Transcript

Jan 2021

PPT

Aug 2020

PPT

Feb 2020

PPT

FAQ's For Zydus Lifesciences Ltd Quarterly Result

What is the EPS of Zydus Lifesciences Ltd stock?

The Earnings Per Share (EPS) of Zydus Lifesciences Ltd is 42.51. An EPS is the amount of net income attributed to each share of a common stock.

How is Zydus Lifesciences Ltd EPS calculated?

The EPS of Zydus Lifesciences Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Zydus Lifesciences Ltd report its EPS?

Zydus Lifesciences Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Zydus Lifesciences Ltd EPS?

Factors that influence the EPS of Zydus Lifesciences Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Zydus Lifesciences Ltd EPS growth indicate future performance?

Yes, consistent growth in Zydus Lifesciences Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*